article thumbnail

COVID-19 has accelerated adoption of non-contact patient monitoring technology, says Frost & Sullivan analysis

Healthcare IT News - Telehealth

According to the analysis by Frost & Sullivan, non-contact patient monitoring technologies are gravitating toward the use of video, sound analysis and mobile-based platforms incorporating advanced technologies such as machine learning and artificial intelligence (AI) algorithms. THE LARGER CONTEXT.

article thumbnail

Pharma – 2025 Health IT Predictions

Healthcare IT Today

This transformation will particularly benefit organizations that can effectively combine AI expertise with traditional pharmaceutical knowledge, creating new competitive advantages in drug development efficiency, cost management, and market responsiveness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership to Propel Cancer Drug Development with AI Digital Cell Clones

Digital Health Global

Key Highlights of the Partnership: 1) Expanding Indications : The partnership will harness TNL’s AI Digital Cells Lab platform to explore additional indications for one of Debiopharm’s cancer drugs. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.

article thumbnail

Quibim: $50M Series A for Precision Medicine with AI-Powered Imaging Biomarkers

Healthcare IT Today

Driven by several regulatory approvals and global commercial partnerships, patient analysis surged by 168% quarter-on-quarter. Their FDA-approved precision analysis is already being used by doctors to detect early signs of diseases like cancer and help measure treatment response.

article thumbnail

Drug Discovery and Early Development Outsourcing Services Industry Analysis – M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion – ResearchAndMarkets.com

Digital Health Global

Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.

article thumbnail

Merative formerly IBM Watson Health poised to launch raft of new products in 2025

Lloyd Price

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today! Subscribe Today!

article thumbnail

The next revolution in the pharmaceutical industry: the transformative potential of AI

Digital Health Global

Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care. AI algorithms come into play in this complexity by orchestrating the analysis of intricate molecular dynamics.